Trial Profile
A Multicenter, Randomized, Double-blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium in Association With Intermittent Pneumatic Compression (IPC) Versus IPC Used Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdomi
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Acronyms APOLLO
- Sponsors GlaxoSmithKline; GSK
- 24 Apr 2008 Status changed from in progress to completed. reported by ClinicalTrials.gov.
- 18 Sep 2007 Results have been reported.
- 14 Sep 2006 New trial record.